Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Deals

Jiangsu Hillgene Biopharma Secures Tens of Millions in Series A Financing for Cell Therapy R&D

Fineline Cube Apr 10, 2023

China-based cell therapy-focused Contract Development and Manufacturing Organization (CDMO) Jiangsu Hillgene Biopharma Co., Ltd has...

Company

Forecyte Bio Expands with New Cell and Gene Therapy GMP Facility in Shanghai

Fineline Cube Apr 10, 2023

Maryland-based Contract Development and Manufacturing Organization (CDMO) Forecyte Biotechnologies has announced the opening of a...

Company Drug

Yiling Pharmaceutical’s XY0206 Advances to Phase III Trial for FLT3-ITD AML

Fineline Cube Apr 10, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced its plans to initiate a Phase...

Company Medical Device

Jiangsu Yuyue Medical Secures NMPA Approval for Semi-Automatic External Defibrillator

Fineline Cube Apr 10, 2023

Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (SHE: 002223), a China-based medical device company,...

Company Drug

MicuRx Pharmaceuticals Initiates Phase III Study for MRX-4 in Diabetic Foot Infection Treatment

Fineline Cube Apr 10, 2023

Sino-US firm MicuRx Pharmaceuticals Inc. has announced the initiation of a Phase III clinical study...

Company Deals

AstraZeneca Partners with Guangzhou Institute to Advance Respiratory Medicine Research

Fineline Cube Apr 10, 2023

UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced a partnership with China’s Guangzhou Institute...

Company Policy / Regulatory

Indonesia and China Deepen Healthcare Ties with High-Level Dialogue and New Agreements

Fineline Cube Apr 10, 2023

Indonesia’s deputy minister of health, Dante Saksono Harbuwono, visited China last week as part of...

Policy / Regulatory

Shanxi Province Begins Historical Procurement Data Collection for Pacemaker VBP Round

Fineline Cube Apr 10, 2023

In preparation for a volume-based procurement (VBP) round, Shanxi province has initiated the gathering of...

Company Drug

TYK Medicines Secures FDA Approval for Next-Generation TKI Clinical Trial

Fineline Cube Apr 10, 2023

China-based TYK Medicines, Inc. has announced that it has received clinical trial approval from the...

Company Deals

Sequanta Technologies Partners with Element Biosciences to Expand Single-Cell Applications

Fineline Cube Apr 10, 2023

Shanghai-based Sequanta Technologies, a leading multi-omics research and clinical service provider, has announced a strategic...

Policy / Regulatory

Fujian Healthcare Security Bureau Updates Sunshine Procurement Mechanism for Drugs

Fineline Cube Apr 10, 2023

The Fujian Provincial Healthcare Security Bureau has released the Notice on Adjusting and Improving the...

Company Drug

Yifan Pharmaceutical Receives NMPA Approval for Hyruan ONE in Knee Osteoarthritis Treatment

Fineline Cube Apr 10, 2023

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced receiving market approval from the National...

Company Legal / IP

Junshi Biosciences Challenges Alynlam’s PCSK9 siRNA Patent with CNIPA

Fineline Cube Apr 7, 2023

Junshi Biosciences (SHA: 688180) is reportedly taking steps to challenge a key patent held by...

Company Deals Digital

ApolloBio Partners with Baidu Health to Enhance Marketing of IgM Nano Immunoglobulin Spray

Fineline Cube Apr 7, 2023

Guangzhou-based biotech ApolloBio has signed a strategic cooperation agreement with Baidu Health. Under this partnership,...

Policy / Regulatory

China’s Provincial Governments Implement Second Batch of National Drug Use Monitoring Policy

Fineline Cube Apr 7, 2023

In line with a notification issued by the National Health Commission (NHC) in January, provincial...

Company Drug

Yantai Dongcheng Pharmaceutical Gets Singapore Regulatory Approval for 177Lu-LNC1004 Phase I Study

Fineline Cube Apr 7, 2023

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving the green light...

Company Medical Device

AcoStream Second-Generation Receives NMPA Marketing Approval for Peripheral Vascular Use

Fineline Cube Apr 7, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving marketing approval from the National...

Company Deals

Shenzhen Kangtai Biological Partners with Biotis for 13-Valent Pneumococcal Vaccine in Indonesia

Fineline Cube Apr 7, 2023

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has struck a partnership with Indonesian...

Company Deals

Harbour BioMed and AstraZeneca Partner to Advance Pharmaceutical Innovation in Yangtze River Delta

Fineline Cube Apr 7, 2023

Harbour BioMed (HKG: 2142), a biotech with operations in the United States, the Netherlands, and...

Company Deals

Shuwen Biotech’s Subsidiary Signs Promotion Agreement with Sysmex Europe for Breast Cancer Detection Product

Fineline Cube Apr 7, 2023

China-based diagnostic specialist Shuwen Biotech Co., Ltd announced that its wholly-owned German subsidiary, Cerca Biotech...

Posts pagination

1 … 593 594 595 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.